Estrogen most reliably eases hot flashes and night sweats, protects bone against fractures, and restores vaginal and urinary comfort after menopause. Possible gains for lifespan, arteries, blood sugar, and the aging brain look strongest when started near menopause. Risks include blood clots, stroke, gallbladder trouble, and breast cancer when combined with a second hormone. (Full Review)

Protocol

Preferred Form

Transdermal 17β-estradiol

Patch 0.025–0.1 mg/day; oral estradiol 1–2 mg/day as an alternative

With a Uterus

Add a progestogen

Micronized progesterone 100–200 mg to oppose endometrial overgrowth

Dosing Schedule

Steady delivery

Patch changed twice weekly, gel each morning, oral estradiol at night

Time to effect

Hot Flashes & Sleep

Days to weeks

Hot flashes and sleep often improve within days to a few weeks

Vaginal Symptoms

Several weeks

Vaginal symptoms improve over several weeks

Bone Benefits

Months

Bone benefits accrue over months and require sustained use

Benefits

High: Relief of hot flashes and night sweats; prevention of bone loss and fractures; relief of genitourinary syndrome of menopause

Medium: Lower death rate when started near menopause; improved artery function and early-menopause heart protection; better sleep quality; reduced type 2 diabetes risk

Low: Reduced dementia risk with early estrogen-only therapy; preservation of skin collagen and elasticity; colorectal cancer reduction with combined therapy

Speculative: Preservation of muscle mass and strength with resistance training; slowing of biological aging processes

Contraindications

Personal history of breast or other estrogen-sensitive cancer

Unexplained vaginal bleeding

Active or prior venous thromboembolism or known thrombophilia

Active liver disease

Recent heart attack or stroke (within 90 days)

Known or suspected pregnancy

Key Interactions

Enzyme-inducing drugs (rifampin, carbamazepine, phenytoin, some HIV medicines)

Enzyme inhibitors (ketoconazole, ritonavir)

Levothyroxine

High-dose acetaminophen

St. John's Wort

Phytoestrogens (soy isoflavones, red clover), DIM, licorice

Grapefruit

Other hormones (testosterone, thyroid hormone), selective estrogen receptor modulators

Risk & Side Effects

High: Venous blood clots; stroke; breast cancer with combined estrogen–progestogen therapy; endometrial overgrowth and cancer from unopposed estrogen; gallbladder disease

Medium: Coronary heart disease when started late; breast tenderness, bloating, and breakthrough bleeding

Low: Ovarian cancer; elevated triglycerides with oral therapy

Speculative: Meningioma; estrogen excess effects in men

Monitoring

Marker	Target	Why
Blood pressure	< 120/80 mmHg	Estrogen and route affect vascular risk
Estradiol	~ 40–100 pg/mL on therapy	Confirms absorption and guides dose
Follicle-stimulating hormone	Elevated (> 25–30 IU/L) off therapy	Confirms menopausal status
Triglycerides	< 100 mg/dL	Oral estrogen can raise triglycerides
Low-density lipoprotein cholesterol	< 100 mg/dL (lower if high cardiovascular risk)	Tracks vascular risk that estrogen modifies
Fasting glucose / HbA1c	< 90 mg/dL / < 5.4%	Estrogen influences insulin sensitivity
Liver enzymes (ALT/AST)	Within normal limits, low-normal preferred	Oral estrogen is liver-metabolized
Bone density (DEXA T-score)	Above −1.0	Verifies bone-protective benefit

Cadence: Symptom and blood-pressure review at 6–12 weeks, reassessment at 6–12 months, then annually; mammography and blood pressure at least annually; lipids and glucose every 1–2 years; bone density every 1–2 years when bone is a target

Qualitative Assessment

Frequency and severity of hot flashes and night sweats
Sleep quality and duration
Daytime energy and cognitive clarity
Mood and emotional steadiness
Vaginal comfort, urinary health, and sexual function
Absence of new adverse signs such as leg swelling, chest symptoms, or abnormal bleeding

Estrogen for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment